BM 519
Latest Information Update: 26 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 12 Jul 2000 New profile
- 12 Jul 2000 Preclinical development for Thrombosis in Belgium (Unknown route)